Last update Jan. 29, 2022
Sulfonamide with properties similar to those of sulfamethoxazole. Used topically (dermatological and vaginal) for the treatment of susceptible infections.
Since the last update we have not found any published data on its excretion in breast milk.
The small dose and poor plasma uptake of most topical dermatological preparations make it very unlikely that significant amounts will pass into breast milk.
Vaginally it can be absorbed in variable quantity (PDR 2019). Do not use vaginally during the neonatal period and in deficit of glucose-6-phosphate dehydrogenase. (AEHH2012)
Sulphamides are excreted in small amounts in breast milk: 6 to 94 micrograms/ml, 1.6% of the total dose. (Briggs 2015)
Reports of adverse effects are rare (Briggs 2015). Avoid in suspected glucose-6-phosphate dehydrogenase deficiency.
Due to the greater toxicity than that of other antimicrobials and their high acquired resistance, the use of sulfonamides is currently very scarce. (Pérez 2003)
Do not apply on the breast so as to avoid its ingestion by the infant; alternatively clean before breastfeeding.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM